Barclays assumes coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Equalweight rating and a price target of $19.00.Analyst Gena Wang ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE